Loading stock data…
ANVS
$2.00+0.03 (+1.52%)
Market ClosedLast close May 1
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annovis Bio, Inc. in the Healthcare sector is trading at $2.00. The stock is currently near its 52-week low of $1.42, remaining 25.1% below its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why ANVS maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.00
Potential Upside
5%
Whystock Fair Value$2.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$63.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-167.04%
Volume
Today's trading volume
701,280
Recent News
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap
Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046. The company, which works on drugs for brain-related diseases, […]
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.